Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
In: König, D; Schär, S; Vuong, Diem; Guckenberger, Matthias; Furrer, K; Opitz, I; Weder, W; Rothschild, 2022
Online
academicJournal
Zugriff:
Titel: |
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
|
---|---|
Autor/in / Beteiligte Person: | König, D ; Schär, S ; Vuong, Diem ; Guckenberger, Matthias ; Furrer, K ; Opitz, I ; Weder, W ; Rothschild, S I ; Ochsenbein, A ; Zippelius, A ; Addeo, A ; Mark, M ; Eboulet, E I ; Hayoz, S ; Thierstein, S ; Betticher, D C ; Ris, H-B ; Stupp, R ; Curioni-Fontecedro, A ; Peters, S ; Pless, M ; Früh, M |
Link: | |
Zeitschrift: | König, D; Schär, S; Vuong, Diem; Guckenberger, Matthias; Furrer, K; Opitz, I; Weder, W; Rothschild, 2022 |
Veröffentlichung: | BMJ Publishing Group, 2022 |
Medientyp: | academicJournal |
ISSN: | 2059-7029 (print) |
DOI: | 10.5167/uzh-220870 |
Schlagwort: |
|
Sonstiges: |
|